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Bacteria have the incredible ability to develop resistance to
the actions of toxic compounds and to adapt rapidly to a
changing environment. To a large extent, such developments
are due to the enhanced expression of drug resistance systems
in these organisms. The introduction of antibiotics in the 20th
century was an important step towards the control of infectious
diseases. Antimicrobials increased the average life expectancy
of humans by drastically reducing the lethal effects of infec-
tious diseases (20). However, quickly after the introduction of
antibiotics, bacteria developed various ways to reverse their
actions (70, 71, 94, 148). Consequently, diseases which were
thought to be under control were again on the upswing. The
causative agents of reemerging infectious diseases increasingly
withstand the action of drug-based medical treatment by the
development of (multi)drug resistance (MDR) mechanisms
(20, 70, 71, 94, 137).
Bacteria exhibit a wide range of mechanisms to resist the
actions of noxious agents. These systems can be specific for a
drug or a group of closely related drugs, such as the enzymatic
inactivation of toxic compounds. -Lactamase, which hydro-
lyzes the -lactam ring of antibiotics (43, 56, 146), is a classic
example of such a mechanism (for a review, see reference 29).
Another mechanism of resistance is the mutational alteration
of the drug target to reduce the target’s affinity for the drug
(43, 56, 146; reviewed in reference 130) or to reduce the per-
meability of the cell envelope. Bacteria are surrounded by at
least one lipid bilayer, the cytoplasmic membrane that, among
others, acts as a general barrier to prevent drug influx into the
cell. Gram-positive bacteria are surrounded by a thick cell wall
made of peptidoglycan which offers only minor resistance to
the diffusion of small molecules. Gram-negative bacteria con-
tain an additional membrane, the outer membrane, which is
less permeable to lipophilic drugs. Finally, mycobacteria have
developed a more effective diffusion barrier consisting of a
thick extracellular layer of mycolic acid (reviewed in reference
96). A decrease of the permeability of the cell envelopes of
gram-negative bacteria and mycobacteria can be achieved by
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decreasing the expression of the porins. These proteins serve
as entry gates for small molecules, in particular nutrients, but
they also facilitate the passage of noxious agents (reviewed in
reference 96).
A general strategy to prevent the cellular entry of drugs is
their active efflux from the cell or the cytoplasmic membrane
(114). These active extrusion mechanisms involve integral
membrane proteins that utilize metabolic energy to expel drugs
across the cytoplasmic membrane against their concentration
gradients. In gram-negative bacteria, active efflux mechanisms
can be coupled to extrusion across the outer membrane. In that
case, an outer membrane pore is involved, which together with
an adaptor protein, forms a bridge between the cytoplasmic
membrane and the outer membrane. Active drug efflux mech-
anisms can be specific for a given drug, so-called single-drug or
group-specific efflux systems, or can have a broad substrate
specificity covering a wide range of toxic compounds that are
structurally and functionally unrelated. The latter process is
termed multidrug efflux. Based on bioenergetic criteria, trans-
porters contributing to MDR (MDR transporters) can be clas-
sified into two main groups, namely, proton motive force
(PMF)- and ATP-dependent transporters. Here we review the
current knowledge of bacterial ATP-dependent MDR pro-
teins, with special emphasis on their distribution in bacterial
genomes and their functional importance to the MDR pheno-
type.
What Is MDR?
Antibiotic resistance emerged and was noticed quickly after the
introduction of the first antibiotics in medical practice. When
other classes of antibiotics were used, the resistant microbes were
found to also be resistant to these drugs even though they had
never been exposed to them. This indicated that these organisms
had developed multiple resistances against a range of drugs. The
molecular basis of the MDR phenomenon was first observed in
mammalian cells (24, 25, 61, 106). Mammalian cancer cells may
develop an MDR phenotype upon exposure to cytotoxic agents
used in cancer therapy. The resistance developed protects the
cells not only against the drug used in chemotherapy but also
against a range of structurally and functionally unrelated toxic
agents (74, 136). Obviously, this seriously undermines the success
of further drug therapies. The major causes of MDR are efflux
pumps such as P-glycoprotein (19; for a review, see reference 6),
the MDR-associated protein MRP1 (21; for a review, see refer-
ence 66), and the breast cancer resistance protein BCRP (5, 34,
90; for a review, see reference 33), which have been characterized
in great detail. During the last decade, a large number of MDR
transporters have also been discovered in prokaryotes. The first
bacterial drug-specific efflux pump was described by Levy and
McMurry in 1978 (72). About 10 years later, a plethora of MDR
transporters had been described for bacteria, such as QacA from
Staphylococcus aureus (135) and EmrE (79) and AcrAB (85, 86)
from Escherichia coli. The multidrug efflux phenomenon is now
recognized as an important mechanism contributing to bacterial
resistance to valuable clinical antibiotics. MDR bacteria can also
display resistance towards cytotoxic agents that they have never
encountered, and thus their activity presents a major threat for
drug-based clinical treatments.
Classification of MDR Transporters
MDR transporters can be classified into the following two
main groups according to the mode of energy coupling to drug
export across the cytoplasmic and outer membranes (Fig. 1):
(i) primary active transporters that belong to the ATP binding
cassette (ABC) superfamily and utilize the free energy of ATP
hydrolysis to expel the drug from the cell against its concen-
tration gradient and (ii) secondary transporters that utilize the
PMF (or sodium motive force) for drug expulsion. The latter
systems function as drug/H or drug/Na antiporters. Second-
ary MDR transporters can be subdivided further into several
families on the basis of their amino acid sequence homology
and predicted secondary structure. These are transporters of
(i) the major facilitator superfamily (MFS) (87), (ii) the small
MDR (SMR) family (108), (iii) the resistance-nodulation-cell
division (RND) family (123), and (iv) the multidrug and toxic
compound extrusion (MATE) family (16) (Fig. 1). This classi-
fication is generally used (73, 114), although other classifica-
tions have been proposed as well (120, 122). Several reviews
dedicated to the classification and global description of MDR
transporter families can be found elsewhere (73, 103, 105, 114,
121, 138). Here we focus on the MDR transporters belonging
to the ABC superfamily.
Distribution of MDR Transporters
Historically, the first cloned and characterized MDR trans-
porters were members of the ABC superfamily of eukaryotic
origin, such as P-glycoprotein (19) and MRP1 (21). In the early
1990s, the bacterial MDR systems were described for the first
time, and these belonged to the group of secondary active
transporters (106). The first bacterial ABC-type MDR protein,
LmrA from Lactococcus lactis, was described in 1996 (143).
FIG. 1. Schematic representation of the major families of MDR
transporters in prokaryotes. Primary transporters that utilize the en-
ergy of ATP hydrolysis belong to the superfamily of ABC transporters.
In prokaryotes, these MDR transporters are so-called half-transport-
ers that either homo- or heterodimerize to form a functional unit.
Secondary transporters energized by the PMF include MFS members,
which are monomeric; SMR family members, which form homo- or
hetero-oligomers; and RND family members, which are tripartite sys-
tems that consist of an integral membrane transporter domain, a fusion
protein (MFP), and an outer membrane protein (OMP). Secondary
transporters energized by the sodium motive force include those in the
MATE family. OM and CM, outer and cytoplasmic membranes, re-
spectively.
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The overwhelming majority of reported bacterial MDR sys-
tems, however, belong to the group of secondary transporters,
and for some time it was believed that primary MDR systems
are uncommon in bacteria (73). The recent completion of the
genome sequences of many different bacteria, most of which
have been poorly studied, now provides a more complete view
of the distribution of MDR-like transporters. Saier and col-
leagues have classified the wealth of this sequence information
on membrane transport proteins in terms of transport mode,
energy-coupling mechanism, molecular phylogeny, and sub-
strate specificity (120). This information is available at http:
//www-biology.ucsd.edu/msaier/transport/. (The transport
classification system has been approved and recommended by
the Nomenclature Committee of the International Union of
Biochemistry and Molecular Biology.) A relational database
(TransportDB) that classifies and predicts the membrane
transporters from organisms whose genomes have been se-
quenced is available at http://membranetransport.org (115).
Sequence analysis of various microbial genomes revealed
that both primary and secondary transporters are ubiquitous in
bacteria. Their relative presence varies among bacterial species
and often correlates with the mode of energy generation. For
instance, fermentative bacteria tend to rely more on the pri-
mary transporters, whereas aerobic bacteria often contain a
larger number of secondary MDR transporters (107, 109).
Paulsen performed a comparative genomic analysis of micro-
bial drug efflux systems and concluded that such systems are
common in prokaryotes (104). However, the number and type
of transporters differ among these microorganisms. For in-
stance, archaea contain a large number of putative MFS-type
efflux pumps, whereas Mycoplasma species and other microbial
parasites utilize mostly ABC-type drug transporters. Neverthe-
less, the MFS and ABC types of MDR transporters appear to
be the most abundant drug efflux systems in prokaryotes (106).
It is important that for only a few of the annotated and pre-
sumed MDR transporters have the catalytic activity and in-
volvement in the MDR phenotype been demonstrated. Many
of the uncharacterized systems may not actually encode MDR
transporters but rather may encode more specialized systems
for metabolites or other compounds.
STRUCTURE AND FUNCTION OF PROKARYOTIC MDR
ABC-TYPE TRANSPORTERS
The ABC superfamily comprises transporters involved in
either uptake or secretion but also includes ABC ATPases that
are not involved in transport but instead fulfill roles in cellular
processes such as DNA repair, translation, or regulation of
gene expression. The functional classification of the ABC sys-
tems was recently reviewed by Dassa et al. (14, 27), and a
database is available at www.pasteur.fr/recherche/unites/pmtg
/abc/index.html. The ABC transporter family is the largest of
all paralogous protein families (46). The first described ABC
transporter, the histidine permease, was cloned and sequenced
in 1982. In 1986, Higgins et al. (47) described a large super-
family of ABC transporters involved in various cellular pro-
cesses. The diagnostic feature of this family is the motor do-
main that binds and hydrolyzes ATP. This domain contains a
number of characteristic and conserved amino acid sequence
motifs. More than 20 years of research have now resulted in
the identification of thousands of ABC ATPases (14), and it
has become evident that the ABC superfamily is distributed
ubiquitously in all three phyla of life (28, 45, 46, 49, 51, 59, 60,
64, 67, 77, 126, 140).
ABC transporters are membrane proteins that are respon-
sible for the uptake and secretion of a wide range of substrates,
from ions and small molecules such as amino acids, sugars,
xenobiotics, and vitamins up to polymers such as peptides,
proteins, and polysaccharides. Because of their wide substrate
range, ABC transporters have been implicated in a range of
cellular processes, such as nutrition uptake, xenobiotic protec-
tion, extrusion of cellular waste products, bacterial immunity
and virulence, osmotic stress, lipid transport, and export of
macromolecules during biogenesis, differentiation, and patho-
genesis (45, 46, 60). The minimal structural organization of an
ABC transporter is the presence of four domains, i.e., two
nucleotide binding domains (NBDs) and two transmembrane
permease domains (TMDs) (48). These four modules are en-
coded either by four different genes or by fewer genes that
specify polypeptides consisting of a fusion of the two NBDs,
the two TMDs, one NBD with one TMD, or even the complete
ABC transporter. This remarkable modular organization fur-
ther discriminates uptake from extrusion systems. Uptake sys-
tems usually consist of four separate polypeptides that together
constitute an active transporter, and in addition, they include
an extracellular substrate binding protein that donates the sub-
strate to the permease domain. Extrusion systems are com-
posed of a homo- or heterodimeric organization in which one
NBD is fused with one TMD (half-transporter). In eukaryotes,
ABC transporters are also found as single proteins in which all
domains are present (full transporters).
The four-domain organization is both sufficient and neces-
sary to form a functional ABC transporter. Some ABC trans-
porters contain additional domains or auxiliary proteins, such
as extracellular binding proteins in bacterial uptake systems
(51, 150) or additional transmembrane helices in the TMDs.
The TMDs usually consist of six transmembrane -helices.
This topology has been demonstrated biochemically and was
confirmed in the crystal structures of the recently described
MDR transporters from Staphylococcus aureus Sav1866 (31)
(Fig. 2). There is relatively little sequence identity between the
TMDs of various ABC transporters, and this is likely a reflec-
tion of the large diversity of the substrates transported. The
TMDs of some ABC transporters deviate from the 66 ca-
nonical arrangement, such as the BtuCD subunits of the vita-
min B12 uptake system, which comprises 10 transmembrane
-helices per subunit (78) (Fig. 2). Because of the nucleotide
binding fold, the NBD is the most conserved domain of the
ABC transporters. It acts as the motor domain that binds and
hydrolyzes ATP in order to elicit conformational changes in
the TMDs to allow transmembrane transport. The NBDs con-
tain highly conserved amino acid sequence motifs that are
involved in nucleotide binding and coordination of the Mg2
ions, i.e., the Walker A (G-X-X-G-X-KS/T) and B (h-h-h-h-D,
where “h” is a hydrophobic residue) motifs (145). These motifs
are characteristic of P-loop ATPases which, besides membrane
transport, are involved in diverse cellular processes, such as
receptor signaling, phosphoryl transfer reactions, motility,
ATP synthesis, DNA translation, and DNA maintenance and
repair (60). In addition, ABC transporters contain a number of
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unique motifs, such as the C loop or ABC signature (L-S-G-
G-Q), which represents a diagnostic motif for the entire su-
perfamily, the Q loop (32), and the H loop (75). A large
number of isolated NBDs have been crystallized and their
three-dimensional structures determined. The NBD functions
as a dimer. Remarkably, isolated NBDs have been crystallized
in various dimeric forms (reviewed in references 60 and 64).
However, in the physiologically active dimeric state, the ABC
signature of one monomer complements the ATP binding site
formed by the Walker A and B motifs. This structure was
initially observed in the Rad50 structure (52), with several
isolated NBDs, and more recently, also with complete trans-
porters. The dimer interface in these structures is in agreement
with biochemical data and is therefore considered to represent
the physiological arrangement.
Most ABC transporters exhibit high specificities for their
respective substrates or a group of closely related compounds.
However, the MDR ABC transporters are polyspecific and can
accommodate a variety of unrelated substrates. Here we dis-
cuss several examples of bacterial MDR ABC-type transport-
ers (Table 1). Single-drug-resistance ABC transporters that are
specific for a given drug or closely related group of substrates
FIG. 2. Structures of prokaryotic ABC-type transporters. (Left) Sav1866 from Staphylococcus aureus (PDB accession no. 2HYD). Sav1866 is
a homodimeric ABC transporter, with the individual subunits colored brown and green, respectively. The bound ADP is shown in ball and stick
representation. (Right) Vitamin B12 transporter BtuCD of E. coli (PDB accession no. 1L7V). BtuCD belongs to the ABC superfamily of proteins
and consists of four separate subunits. The two TMDs of BtuC are colored green and blue, respectively, and the two NBDs are colored orange
and yellow, respectively. The figure was prepared using the PyMol program and the respective PDB files.
TABLE 1. Bacterial multidrug efflux systems of the ABC superfamily
Organism Protein Established substratesb Reference
Lactococcus lactis LmrA DA, EB, H, R6G, TPP, various antibiotics 143
LmrCDa DA, EB, H, R6G, CHO, BCECF-AM 81
Lactobacillus brevis HorA EB, H, hop compounds 125
Bacillus subtilis BmrA (YvcC) H, DO, AD 131
Enterococcus faecalis EfrABa AC, EB, SO, DAPI, DA, DO, NB, AK, DC, NF 30
Abc7 DA, DO, EB, OF, CM
Abc11 PT, CH
Abc16 AZ, EM, CR,
Abc23 CL, LM, VM, SC
Oenococcus oeni OmrA SL, CdCl2 15
Vibrio cholerae VcaM H, TC, CF, NF, OF, DA, DO, DAPI, TTP,
R6G, EB, AO
54
Streptococcus pneumoniae SP2073/SP2075a AC, BB, EB, CF, NF, NB, CL 118
a Two half-transporters that assemble into a heterodimeric functional unit.
b Abbreviations: AC, acriflavine; AD, 7-aminoactinomycin D; AK, arbekacin; AO, acridine orange; AZ, azithromycin; BB, berberine; BCECF-AM, acetoxymethyl
ester 2,7-bis-(2-carboxyethyl)-5(and 6)-carboxyfluorescein; CF, ciprofloxacin; CH, chlorhexidine; CHO, sodium cholate; CL, clindamycin; CM, chloramphenicol; CR,
clarithromycin; DA, daunomycin (daunorubicin); DC, doxycycline; DO, doxorubicin (adriamycin); EB, ethidium bromide; EM, erythromycin; H, Hoechst 33342; LM,
lincomycin; NB, novobiocin; NF, norfloxacin; OF, ofloxacin; PT, pentamidine; R6G, rhodamine 6G; SC, Synercid; SL, sodium laureate; SO, safranin O; TC,
tetracyclines; TPP, tetraphenylphosphonium; and VM, virginiamycin M.
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as well as atypical ABC proteins involved in drug resistance but
lacking obvious TMDs are not included in this review.
ABC-TYPE MDR TRANSPORT SYSTEMS IN
GRAM-POSITIVE BACTERIA
ABC-type MDR transporters are relatively poorly charac-
terized for both gram-positive and -negative bacteria. Recent
reviews on efflux-based resistance mechanisms in bacteria even
highlight the importance of multidrug transport systems ener-
gized by the PMF (or sodium motive force) (73, 112). How-
ever, functional analysis approaches indicate that the role of
ABC MDR transporters in MDR has been underestimated.
Most of the described MDR transporters in gram-positive bac-
teria characterized thus far are secondary MDRs, such as
QacA (MFS) (135), NorA (MFS) (149), and Smr (SMR fam-
ily) (39) from Staphylococcus aureus, the NorA homologs Bmr
and Blt (3, 95) from Bacillus subtilis, PmrA from Streptococcus
pneumoniae (38), and LmrP from Lactococcus lactis (13).
However, several examples of primary MDR pumps, discussed
further below, can be found in gram-positive bacteria. It should
be stressed that the functional analysis of ABC-type MDR
transporters in bacteria is still in its early stage and often
incomplete.
Lactococcus lactis
L. lactis is a nonpathogenic bacterium that has served as an
excellent model system for studies of MDR. The genome of L.
lactis contains 40 putative drug transporter genes, only a few of
which have been characterized functionally (83). The first ex-
perimental evidence for efflux-based resistance of L. lactis
against a variety of toxic compounds dates back more than 10
years. Selection of L. lactis mutants that could grow in the
presence of toxic compounds, such as ethidium, rhodamine,
and daunomycin, resulted in strains which were not only resis-
tant to the selection drug but also cross-resistant to structurally
unrelated drugs (12). The resistance was shown to be due at
least partly to active efflux of the drugs. Moreover, bioener-
getic studies demonstrated that the efflux activity was either
ATP or PMF dependent (12). Studies directed to identify and
characterize the molecular basis of the observed efflux activi-
ties resulted in the discovery of several MDR transporters in
this organism (Fig. 3). Among these systems are the first de-
scribed ABC-type MDR transporter in prokaryotes, LmrA
(143); a member of the MFS, LmrP (13); and the recently
described heterodimeric ABC MDR transporter, LmrCD (81).
In addition, in silico analysis of the genome of L. lactis IL-1403
revealed the presence of an additional 36 putative MDR trans-
porters (83).
LmrA. The LmrA protein was termed lactococcal multidrug-
resistant protein ATP. The lmrA gene was discovered acciden-
tally, neighboring the apl (alkaline phosphatase-like enzyme)
gene on a cloned chromosomal DNA fragment. The lmrA gene
specifies a protein that shares structural homology with the
well-characterized human P-glycoprotein. Unlike P-glycopro-
tein, LmrA is a half-transporter which functions as a ho-
modimer. lmrA was expressed in a drug-hypersensitive strain of
E. coli CS1562 (tolC) for functional studies. Expression of
LmrA renders this E. coli strain resistant to ethidium, dauno-
mycin, rhodamine 6G, and tetraphenylphosphonium (TPP)
(143) and to a multitude of antibiotics, such as aminoglyco-
sides, lincosamides, macrolides, quinolones, streptagramins,
tetracyclines, and chloramphenicol (113). Transport of
ethidium and daunomycin was demonstrated in cells and in-
side-out membrane vesicles, respectively (143). Recently, the
heterologously expressed LmrA protein was also postulated to
confer protection on E. coli strain CS1562 (tolC) against high
salt stress, sodium laureate, and ethanol toxicity (15) and
against cadmium (1). Similar observations have been made for
the Oenococcus oeni OmrA protein, a homolog of LmrA.
LmrA has been shown to restore the growth of E. coli WD2, a
temperature-sensitive mutant of MsbA, at the nonpermissive
temperature (117). Conversely, MsbA expressed in L. lactis
conferred resistance to erythromycin and showed elevated lev-
els of Hoechst 33342 and ethidium transport (147). MsbA in E.
coli is responsible for the transport of lipid A across the cyto-
plasmic membrane and thus plays a role in the biogenesis of
the outer membrane. A role of MsbA in drug resistance in E.
coli has not been documented.
Evidence for a role of LmrA in drug transport mostly orig-
inates from studies with heterologous systems. Its precise role
in drug transport in L. lactis has remained unclear. Cells bear-
ing elevated levels of LmrA have been reported to show en-
hanced ethidium efflux activity (88), but other studies failed to
detect any significant activity above the already high endoge-
nous ethidium extrusion levels (12, 81). Membrane vesicles
bearing high levels of LmrA show an ATP-dependent Hoechst
33342 transport activity, but in vivo, LmrA does not protect
cells against the toxic effect of Hoechst 33342 (139). A recent
study indicated that the LmrA-dependent activity of Hoechst
33342 in membrane vesicles is due to an LmrA-mediated
repartitioning of Hoechst 33342 in response to the transmem-
brane pH gradient generated by the F1Fo ATPase. Hoechst
transport was not coupled directly to the hydrolysis of ATP by
LmrA (139). LmrA has also been purified and reconstituted in
liposomes (88). These proteoliposomes exhibited a very low
level of ATP-dependent Hoechst 33342 transport and flip-flop
of a fluorescent lipid (88). Although in heterologous systems
FIG. 3. Functionally characterized MDR transporters in Lactococ-
cus lactis. Shown are LmrP, a secondary transporter of the MFS;
LmrA, a homodimeric member of the ABC family; and LmrCD, a
heterodimeric member of the ABC family.
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LmrA renders cells resistant to a remarkably broad range of
drugs (113), deletion of the lmrA gene in L. lactis has no effect
on the drug resistance profile of L. lactis (30). Likewise, over-
expression of LmrA in a drug-sensitive L. lactis lmrA lmrCD
strain (see the next section) does not result in protection of the
cells against drugs, suggesting that LmrA is not the major
MDR transporter in this organism. The lack of a phenotype of
the lmrA deletion strain has been attributed to a compensatory
increase in the levels of other MDR transporters, but so far,
this remains to be investigated. It may well be that the ob-
served drug extrusion activity of LmrA in heterologous systems
reflects a minor activity that is observed only upon massive
overexpression. So far, drug export and resistance have not
been attributed to LmrA expressed at wild-type levels, and its
physiological role remains to be elucidated.
LmrA and P-glycoprotein are both structurally and function-
ally related. LmrA overproduced in human fibroblasts localizes
to the plasma membrane and confers MDR on these cells, with
a substrate spectrum similar to that of P-glycoprotein (141).
This has led to the hypotheses that these proteins not only are
distant structural homologs but also share a close functional
homology and that ABC-type MDR transporters are con-
served from bacteria to humans. LmrA has become a model
protein for the study of structural and mechanistic features of
ABC MDR transporters. LmrA is a half-transporter with an
amino-terminal TMD comprising six transmembrane -helices
and a carboxyl-terminal NBD. Covalent linkage of two LmrA
monomers by means of a “linker peptide” derived from P-
glycoprotein yields a functional protein. The introduction of a
mutation into one of the two monomers caused a negative
dominant effect in a lipid flip-flop assay, suggesting that the
protein functions as an oligomer, likely a homodimer (142).
The molecular mechanism of LmrA-mediated drug transport
has been studied in great detail. Photoaffinity labeling and drug
equilibrium binding experiments suggest that LmrA contains
two cooperative drug binding sites which are allosterically
linked (142). This has led to the proposition of a two-cylinder
engine mechanism in which the homodimeric LmrA protein
contains two substrate binding sites that are cooperatively
linked. According to this model, a high-affinity binding site
facing the cytoplasm binds the drug molecule, most likely from
the inner leaflet of the membrane, whereas the second, low-
affinity binding site is exposed to the extracellular milieu. The
two-cylinder model proposes a physical movement of the high-
affinity binding site from inside to outside the cell and a sub-
sequent change from a high- to a low-affinity binding site,
whereupon the substrate is released. This conformational tran-
sition is driven by the hydrolysis of ATP by one of the NBDs.
This reallocation of the binding site would be accompanied by
a reversal of the second binding site, from an outer membrane-
facing to an inner membrane-facing state, accompanied by a
transition from a low- to a high-affinity drug binding confor-
mation. In a next cycle, ATP hydrolysis by the second NBD
would drive the reallocation of the second, drug-loaded bind-
ing site from the inside to the outside, whereas the other empty
drug binding site would reorient towards the inside of the cell.
This model implies a stoichiometry of one molecule trans-
ported per ATP hydrolyzed. Strikingly, in the vanadate-
trapped ADP-bound state of LmrA, only the low-affinity site
was found to be accessible to drugs, whereas the high-affinity
drug binding site appeared occluded. This model resembles the
alternating catalytic site mechanism of ATP hydrolysis sug-
gested for ABC transporters (128).
Recently, the structure of a bacterial ABC exporter, Sav1866
from Staphylococcus aureus (31), which is homologous to
LmrA, was resolved. Sav1866 may specify an MDR trans-
porter, as reconstitution studies demonstrated that its ATPase
activity is stimulated by typical MDR transporter substrates.
The transporter was crystallized in the presence of ADP sand-
wiched between the P loop of one subunit and the signature
motif of the opposite subunit, yielding an outward-facing con-
formation of the proposed binding site. The structural study
suggests an “alternating access and release” transport mecha-
nism. As with the previously discussed model of LmrA, two
binding conformations are proposed, namely, an inwardly fac-
ing state which accepts the substrate and an outwardly facing
state which releases the substrate outside the cell. The energy
required to reorient these two binding sites would be supplied
by ATP binding and hydrolysis. However, this model seriously
deviates from the “two-cylinder engine model” that implies
two reorienting binding sites, as with Sav1866 there is only a
single reorienting binding site. An interesting feature of the
Sav1866 structure is the tight and intertwined association of
the two monomers. It has been suggested that this architecture
allows for a close association of the two NBDs, which makes it
unlikely that they would completely dissociate during the cat-
alytic cycle. This model again differs from other ATP binding
and hydrolysis models, such as the “processive clamp” (55, 92)
and “ATP switch” (49) models.
A truncated version of LmrA in which the NBD was genet-
ically removed, thus leaving only the TMD (LmrA-MD), still
forms a dimeric active unit. Surprisingly, LmrA-MD expressed
in E. coli was reported to mediate the influx of ethidium in
symport with protons. It was suggested that the membrane
domain of LmrA acts as a secondary transporter, i.e., a H/
drug symporter, which would be reminiscent of an evolutionary
ancestor of LmrA that acquired the NBDs as catalytic modules
to become a drug efflux system. With intact LmrA, NBD-
mediated nucleotide binding and hydrolysis are supposed to
reverse the directionality of drug transport as well as of proton
movement (144). According to this hypothesis, ATP-driven
transport of drugs out of the cells would be accompanied by
proton extrusion. Amino acyl residue E314 has been impli-
cated in this proton-coupled ethidium transport by LmrA
(129). Remarkably, the proposed LmrA-mediated proton
movements are energetically unfavorable and seemingly func-
tionally obsolete. In the absence of the NBDs, LmrA would
work as a PMF-driven drug uptake system, while the complete
LmrA protein would function as a proton extrusion system that
acts against the existing electrochemical gradient of protons.
Further studies on the uptake of ethidium suggest that LmrA
present at overexpressed levels mediates ethidium influx into
cells under nonenergized conditions (7). This process is not
dependent on ATP hydrolysis, but instead, ethidium influx
was shown to drive ATP synthesis at LmrA, although the
levels of ATP synthesis reported were infinitely small (about
1 mol of ATP synthesized per mol of LmrA in a time frame
of 30 min; turnover of 0.00056 s1) and barely above the
background levels observed with an NBD-ATPase mutant of
LmrA. Typically, ABC transporters show turnover numbers
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of 10 to 200 s1, which are many orders of magnitude higher
than the ATP synthesis rate reported. Therefore, the signif-
icance of this drug-induced ATP synthesis activity by LmrA
is elusive.
Typically, both glucose-energized L. lactis wild-type and
lmrA cells show a significant ethidium efflux activity that is
preceded by an initial -dependent accumulation of ethidium
(12, 13, 125). This suggests the presence of other MDR trans-
porters involved in ethidium efflux. However, in a recent study
(129), it was claimed that there is no residual ethidium efflux
activity in energized wild-type cells and that ethidium efflux is
observed only upon LmrA overexpression. Currently, the dis-
crepancy in these observations is difficult to explain. However,
both strong functional and genetic evidence suggests that
MDR transporters other than LmrA are involved in endoge-
nous and acquired drug (and ethidium) resistance, as discussed
in the next section. Likewise, transcriptome analysis indicates
that many MDR transporter-like proteins are endogenously
expressed in wild-type cells even when they are not challenged
with drugs.
LmrCD. LmrC and LmrD are two ABC half-transporters
whose genes are organized in a small operon (81). These pro-
teins are homologous to other members of the ABC-type
MDR family, such as LmrA, human P-glycoprotein, and BmrA
from B. subtilis (Table 2). LmrC and LmrD are each composed
of a TMD with six transmembrane segments and a carboxyl-
terminally located NBD. Biochemical evidence demonstrated
that LmrC and LmrD are interacting proteins. They can be
isolated as a stoichiometric complex with a high endogenous
ATPase activity. In contrast, the separately purified subunits
are essentially inactive with regard to ATPase activity (81). L.
lactis cells show a high level of drug extrusion upon overex-
pression of both LmrC and LmrD, whereas no elevated activity
is observed when LmrC and LmrD are expressed separately.
LmrCD substrates identified thus far are drugs that are typi-
cally used in transport assays, such as the fluorescent dyes
acetoxymethyl ester 2,7-bis-(2-carboxyethyl)-5(and 6)-car-
boxyfluorescein (BCECF-AM), daunomycin, ethidium, and
Hoechst 33342 (81). Likewise, LmrCD mediates Hoechst
33342 export from both cells and membrane vesicles (139).
Transport of these drugs is independent of the PMF and re-
quires the ATPase activity of the LmrCD complex. Impor-
tantly, an L. lactis strain lacking the lmrCD genes is hypersen-
sitive to a range of toxic compounds, such as ethidium,
daunomycin, Hoechst 33342, cholate, and rhodamine 6G, but
not to a variety of tested antibiotics or quinine. This sensitivity
to toxicity could be rescued by low-level expression of lmrCD
but not by mutants of LmrCD that are devoid of ATPase
activity (82). Moreover, attempts to reisolate ethidium- and
daunomycin-resistant strains from the L. lactis lmrCD strain
have been unsuccessful, suggesting that at least for this panel
of drugs, there is no functional alternative extrusion route.
These data demonstrate that LmrC and LmrD are involved in
the intrinsic drug resistance of L. lactis.
The nucleotide binding sites of the heterodimeric LmrCD
protein contain partially degenerate sequence motifs. Residues
postulated to interact directly or via H2O with the 	-phosphate
of a bound nucleotide in the LmrC ATP active site, such as the
glutamate following the Walker B motif, a histidine in the H
loop, and the first glycine in the signature motif, are replaced
by aspartate, glutamine, and valine, respectively. These resi-
dues are conserved, however, in the LmrD NBD. It therefore
appears that the LmrCD heterodimer contains structurally
asymmetric ATP binding/hydrolysis sites (82). The functional
state and the contribution of both NBDs to the LmrCD drug
transport activity have been examined. The conserved gluta-
mate directly following the Walker B site of LmrD was re-
placed by a glutamine (“canonical LmrD ATP active site”),
and the corresponding aspartate in LmrC was replaced by an
asparagine (“noncanonical LmrC ATP active site”). The con-
served glutamate was postulated to play an essential role in
ATP hydrolysis as a catalytic base positioning the water mol-
ecule that attacks the 	-phosphate of ATP or to function in
another important step of the ATP hydrolysis cycle (82). Both
the double mutant, LmrC(D495N)/LmrD(E587Q), and the
single mutant, LmrC/LmrD(E587Q), were found to be defec-
tive in ethidium, Hoechst 33342, and BCECF-AM transport,
while L. lactis cells expressing the LmrC(D495N)/LmrD mu-
tant showed a transport activity comparable to that of the
overexpressed wild-type LmrCD protein (82). LmrCD com-
plexes bearing LmrD(E587Q) were found to be completely
defective in ATPase activity, whereas complexes of the
LmrC(D495N) mutant appeared unstable but retained signif-
icant ATPase activity (82). An asymmetric organization of the
NBDs in the LmrCD heterodimer was further supported by
azido-ATP photoaffinity studies. Under nonhydrolyzing condi-
tions, this nucleotide analogue labeled mostly the LmrC sub-
unit, while in the presence of AlFx to trap the hydrolyzed
azido-ATP at the nucleotide binding site, strong labeling of the
LmrD subunit was observed (82). These data suggest that the
heterodimer LmrCD transporter harbors two asymmetric nu-
cleotide binding sites, with a canonical LmrD ATP active site
which is presumably responsible for high ATPase activity and
a slowly hydrolyzing noncanonical LmrC ATP active site.
The two half-transporters LmrC and LmrD in L. lactis in-
teract to form a functional transporter. In eukaryotes, forma-
tion of an active transporter from two different ABC half-
transporters, for instance, the Drosophila white, brown, and
scarlet genes (35) and the fatty acid peroxisomal ABC half-
transporters (76), is a more common feature. In those cases, a
network of interactions was shown to give rise to various pos-
TABLE 2. Amino acid identity between L. lactis LmrCD and MDR
transporters of gram-positive human pathogens
Protein
% Identitya
LmrC LmrD SP2075 SP2073 EF0790 EF0789 Spy0229 Spy0230
LmrC 22 56 23 25 55 56 23
LmrD 22 26 57 60 23 25 60
SP2075 56 26 25 24 57 65 24
SP2073 23 57 25 57 26 24 67
EF0790 25 60 24 57 28 26 62
EF0789 55 23 57 26 28 57 25
Spy0229 56 25 65 24 26 57 24
Spy0230 23 60 24 67 62 25 24
a Percentage of identical residues in pairwise alignments, using the ClustalW
tool available on the World Wide Web at http://www.ebi.ac.uk/clustalw/.
b Data shown are for the following proteins (GenBank accession no.): L. lactis
LmrC (AAK04408) and LmrD (AAK04409), Streptococcus pneumoniae SP2075
(AAK76137) and SP2073 (AAK76136), Enterococcus faecalis EF0790
(AAO80604) and EF0789 (AAO80603), and Streptococcus pyogenes Spy0229
(AAK33312) and Spyo0230 (AAK33313).
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sible heterodimers with different properties. L. lactis contains
another ABC half-transporter besides LmrCD, namely, LmrA,
which has been implicated as an MDR transporter. One could
envision the possibility that these systems may assemble into
different heterodimers that differ in their substrate spectra.
Although this possibility cannot be excluded fully, it is unlikely
for the lactococcal MDR transporters. Namely, analysis of the
lmrCD, lmrA, and lmrCD lmrA strains suggested the
involvement of only LmrCD in the intrinsic drug resistance of
L. lactis. No significant phenotypic changes were recorded for
the lmrA strain, while the lmrCD and lmrCD lmrA strains
showed identical drug susceptibility phenotypes. Moreover,
transcriptome analysis of four different MDR mutants of L.
lactis showed strong up-regulation of the LmrCD operon,
while the expression of the LmrA gene was not significantly
affected. Possibly, the use of mosaic ABC transporters exists in
other bacteria, but this remains to be demonstrated.
Other MDR transporters. The L. lactis genome contains
many genes that specify putative MDR systems (83). To ad-
dress the question of which system(s) is involved in acquired
drug resistance, the gene expression profiles of MDR strains of
L. lactis MG1363 selected for growth in the presence of high
concentrations of ethidium bromide, daunomycin, rhodamine
6G, and cholate were analyzed with DNA microarrays (83).
The MDR strains showed high levels of cross-resistance to a
wide variety of structurally unrelated toxic compounds, sug-
gesting that a specific set of MDR transporters is responsible
for acquired drug resistance (12). Reverse transcription-PCR
analysis showed that in all strains, lmrC and lmrD were signif-
icantly up-regulated (81). Strikingly, this result was confirmed
by DNA microarray analysis, but more importantly, the anal-
ysis showed that lmrC and -D are the only MDR transporter
genes that are highly up-regulated in all tested MDR strains. It
therefore appears that LmrCD is not only an important deter-
minant of the intrinsic drug resistance of L. lactis but also plays
an important role in acquired drug resistance. Apparently, L.
lactis relies on ABC-type MDR transporters for drug resis-
tance rather than on secondary active transporters, as demon-
strated for many other bacteria.
Lactobacillus brevis
HorA is an ABC half-transporter from Lactobacillus brevis
which shares 53% identity with LmrA. L. brevis is a beer spoil-
age bacterium that is able to resist antibacterial hop com-
pounds. The horA gene is plasmid localized in hop-tolerant
strains, and when this plasmid is cured, cells become sensitive
to hop-like compounds (124). Because of its similarity to
LmrA, HorA may be an MDR transporter as well. The protein
has been expressed and functionally characterized in L. lactis
and was shown to confer resistance to hop compounds. In
addition, HorA mediates the excretion of ethidium and
Hoechst 33342 from cells, while Hoechst 33342 transport in
inside-out membrane vesicles was found to be inhibited by hop
compounds (125). Therefore, HorA is an MDR transporter
that renders cells resistant to antimicrobial compounds used as
food preservatives.
Bacillus subtilis
B. subtilis is a soil bacterium with a very versatile metabo-
lism. The genome of B. subtilis contains many putative MDR
transporter genes, but only a few have been characterized.
BmrA (formerly known as YvcC) is an ABC half-transporter
that shares high homology with LmrA (41.5% identity). Het-
erologously expressed BmrA was initially characterized in E.
coli. In inside-out membrane vesicles, the protein exhibits a
high vanadate-sensitive ATPase activity and mediates trans-
port of Hoechst 33342 (131), doxorubicin, and 7-aminoactino-
mycin D (132). BmrA has been purified, reconstituted, and
crystallized in two dimensions. The protein forms ring-shaped
structures with a diameter of about 40 nm. A structural model
of BmrA suggests a homodimeric organization with a central
open chamber between the two subunits and asymmetrically
organized NBDs (18). Time-resolved fluorescence resonance
energy transfer experiments support the formation of a stable
homodimeric protein complex (22). In B. subtilis, the bmrA
gene is expressed throughout growth, while its expression is not
significantly influenced by the presence of typical MDR sub-
strates. Moreover, the deletion of the bmrA gene did not ren-
der cells more sensitive to drugs such as ethidium bromide,
although the overexpression of BmrA supports the notion that
the protein is involved in ethidium efflux and resistance (132).
The ATPase cycle of BmrA has been studied extensively.
The putative catalytic base, the glutamate residue next to the
Walker B site, was subjected to site-directed mutagenesis. The
mutants were found to be devoid of ATPase activity and
showed a vanadate-independent trapping of 8-N3-[-
32P]ATP
at the nucleotide binding site. In wild-type BmrA, vanadate
traps the nucleotide in its hydrolyzed state. This strongly sug-
gests that the glutamate residue is involved in catalysis (102).
Enterococcus faecalis
Enterococcus faecalis is relatively resistant to a large number
of toxic compounds. This has been attributed to the presence
of MDR pumps because the genome of E. faecalis contains a
large number of putative MDR transporters. Systematic gene
inactivation studies with this organism revealed the involve-
ment of ABC-type MDR transporters in drug resistance.
EfrAB is a heterodimeric MDR ABC transporter that is struc-
turally and possibly functionally related to LmrCD of L. lactis.
Expression in E. coli revealed that efrA and efrB render cells
resistant to a range of drugs, such as acriflavine, norfloxacin,
ciprofloxacin, doxycycline, 4,6-diamidino-2-phenylindole
(DAPI), and TPP chloride. EfrAB likely functions as a het-
erodimer since the elevated drug resistance was observed only
when efrA and efrB were coexpressed. Further studies with cells
demonstrated that EfrAB mediates the active efflux of acrifla-
vine (69). In addition, another MDR transporter of E. faecalis
has been characterized partially, i.e., EmeA, a homolog of
NorA from Staphylococcus aureus (57, 68) which is a member
of the MFS.
Oenococcus oeni
omrA is a stress response protein from the wine lactic acid
bacterium Oenococcus oeni. OmrA shares high sequence sim-
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ilarity with LmrA (54% identical residues) and other members
of the ABC-type MDR protein family. The omrA gene is up-
regulated by high temperature and osmotic shock. OmrA was
further characterized in a drug-hypersensitive E. coli strain and
was found to provide resistance to ethanol (but also wine) and
sodium laureate. This resistance was reversed by verapamil, a
known blocker of ABC-type MDR pumps (15). Furthermore,
OmrA but also LmrA and human P-glycoprotein expressed in
E. coli rendered cells more resistant to cadmium toxicity, in a
verapamil-sensitive manner (1). Cadmium is possibly trans-
ported as a glutathione derivative in a similar way to that
shown for human MRP1.
ABC-TYPE MDR TRANSPORT SYSTEMS IN
GRAM-NEGATIVE BACTERIA
One important difference between gram-negative and gram-
positive bacteria is the presence of an outer membrane in the
former. This additional membrane constitutes a major barrier
for the permeation of lipophilic and amphiphilic compounds.
However, the presence of an outer membrane does not suffi-
ciently explain the intrinsic resistance of gram-negative bacte-
ria to drugs (97), and the contribution of MDR efflux pumps to
drug resistance in these bacteria is well established. Special
mechanisms are required to allow the efficient expulsion of
drugs across the cell envelope of the cell. Gram-negative bac-
teria contain MDR transporters in the cytoplasmic membrane
that catalyze the efflux of drugs into the periplasmic space. This
involves mostly members of the SMR and MFS transporter
families. In addition, cells contain tripartite systems that trans-
port drugs across both the cytoplasmic and the outer mem-
brane. The latter systems constitute a complex of three pro-
teins, i.e., a transporter located in the cytoplasmic membrane,
a periplasmic membrane fusion protein, and an outer mem-
brane channel protein (73, 97). These tripartite systems play a
major role in both the intrinsic and acquired resistance of
gram-negative bacteria (73). The AcrAB-TolC system of E.
coli is one of the best-characterized MDR transporters (85,
86). The phenotype caused by its deletion was already de-
scribed in 1965 as a locus disruption which renders E. coli
sensitive to basic dyes, detergents, and hydrophobic antibiotics
(37). This system consists of AcrA, the membrane fusion pro-
tein; AcrB, a transporter of the RND family; and TolC, the
outer membrane protein.
Several members of the RND family have been implicated in
fulfilling a dominant role in MDR in gram-negative bacteria
(for recent reviews, see references 73 and 111). Also, various
transporters of the MATE, MFS, and SMR families, utilizing
the PMF or sodium motive force, have been described (for
reviews, see references 73 and 111). Interestingly, only a very
few members of ABC-type MDR transporter families have
been reported to be involved in drug resistance in gram-neg-
ative bacteria (73, 111). Systematic gene disruption and expres-
sion studies with E. coli did not identify a single ABC-type
MDR transporter involved in drug resistance. Nevertheless, a
small number of ABC-type MDR transporter-like proteins
have been characterized for gram-negative bacteria, and these
are discussed in this section.
Vibrio cholerae
VcaM is an ABC half-transporter that was identified during
a screen for resistance markers in Vibrio cholerae upon expres-
sion in a drug-hypersensitive E. coli strain. VcaM renders E.
coli resistant to several unrelated drugs, such as tetracycline,
norfloxacin, ciprofloxacin, anthracyclines, DAPI, Hoechst
33342, and others. VcaM was demonstrated to transport
Hoechst 33342 and doxorubicin, and this activity was inhibited
by reserpine and vanadate (54). Thus, VcaM seems to repre-
sent the first example of a true ABC-type MDR transporter
from a gram-negative organism. The role of VcaM in its native
host, V. cholerae, has not yet been addressed.
Escherichia coli
E. coli contains five putative ABC-type MDR-like transport-
ers. These systems were all cloned and expressed in a drug-
sensitive E. coli strain, and the drug resistance phenotypes
were investigated. None of these systems provided an appre-
ciable drug resistance to E. coli, except for YbjYZ, which
conferred resistance to erythromycin (100). YbjYZ was re-
named MacAB (macrolide-specific ABC-type efflux carrier)
and characterized as a macrolide-specific transporter confer-
ring resistance to macrolides composed of 14- and 15-mem-
bered lactones (65). A homolog of MacAB has been identified
and characterized in Neisseria gonorrhoeae (119).
ABC-TYPE MDR TRANSPORT SYSTEMS IN ARCHAEA
Genomic sequences of organisms belonging to the archaea
indicate the presence of a multitude of putative MDR trans-
porters, similar to the case for bacteria (115, 116; www
.membranetransport.org). However, only a few experimental
studies have been performed on multidrug transporters in ar-
chaea, even though archaeal genomes contain a greater num-
ber of membrane proteins with unknown function than do
bacterial genomes (116). HsmR of a Halobacterium sp. is a
secondary transporter belonging to the SMR family (99).
There is indirect experimental evidence for the presence of a
P-glycoprotein-like ABC-type MDR transporter in Haloferax
volcanii (91). An anthracycline-resistant mutant of H. volcanii
was shown to transport rhodamine 123 more efficiently than
the wild type. This efflux activity was reduced by the addition of
P-glycoprotein modulators, such as diltiazem, verapamil, or the
Ca2-channel antagonist nifedipine (63, 91).
THE GLOBAL PICTURE OF MDR
With the availability of an increasing number of sequenced
genomes, it has become possible to predict the distribution of
MDR-like transporters in various organisms for comparative
purposes. MDR-like transporters are highly abundant and
ubiquitous in nature. They represent, on average, more than
10% of the total number of transporters per organism (104).
Several questions arise, as follows. Why are there so many
MDR pumps? Do they fulfill redundant or overlapping func-
tions? Which MDR transporters are involved in intrinsic
and/or acquired resistance? Do they contribute to clinical re-
sistance? What is the preferred mode of energization? Does
this differ for organisms and does it relate to their respective
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growth habitat and physiology? What is the physiological role
of MDR proteins? Do they fulfill tasks other than xenobiotic
protection?
Systematic genetic approaches try to answer some of these
questions. Gene knockouts and/or overexpression studies, of-
ten using drug-hypersensitive strains, have proved to be very
useful. In addition, microarray analysis of resistance mutants
can shed more light on the factors that influence acquired
MDR. Such studies can potentially highlight novel antimicro-
bial targets or identify MDR transporters which, upon dele-
tion, will yield hypersensitive drug strains that might be valu-
able tools for cell-based screening of novel antimicrobials (53,
133).
Escherichia coli
The contributions of putative and established MDR proteins
to both intrinsic and acquired resistance have been examined
in great detail. A comprehensive knockout analysis involving
25 transporters, including members of all known MDR fami-
lies, was conducted. Knockout strains were tested for suscep-
tibility towards 20 different classes of antimicrobial com-
pounds. This study revealed that the AcrAB-TolC system is the
major determinant for drug resistance in E. coli (133). AcrB
belongs to the RND family and makes up an MDR transporter
that employs the PMF as a driving force. Several other MDR
transporters provide resistance to a narrow range of com-
pounds. The only putative ABC-type MDR transporter in-
cluded in this study, that encoded by ybjYZ, failed to show any
functional contribution to the intrinsic drug resistance of E.
coli (133).
In addition, complementary studies have been conducted to
identify MDR systems that contribute to the acquired resis-
tance of E. coli (100). This analysis involved 37 proteins with a
presumed role in drug efflux. All of these proteins were ex-
pressed in a drug-hypersensitive strain of E. coli and tested
against 26 antimicrobial compounds. The expression of 16 sys-
tems rendered E. coli cells resistant to various antimicrobials.
This included the AcrAB-TolC transporter, with its broad-
substrate spectrum, and other PMF-dependent systems. Of the
seven proteins belonging to the ABC type of MDR transport-
ers, only YbjYZ (MacAB) conferred resistance to 14- and
15-membered lactone macrolides (100). These studies clearly
demonstrated a central position of AcrAB-TolC in both intrin-
sic and acquired MDR in E. coli and indicated a minor role for
other systems, in particular ABC-type MDR transporters. The
latter systems are likely involved in transport of specific subsets
of molecules, either drugs or metabolism-derived compounds.
Indole, which is metabolically synthesized from tryptophan by
tryptophanase in E. coli, was shown to induce the expression of
a number of MDR pumps. Indole induces acquired multiple
drug resistance in E. coli (50).
Enterococcus faecalis
Bioinformatic analysis revealed the presence in E. faecalis of
34 putative MDR transporters belonging to four different
transporter families, with 23 ABC, 9 MFS, 1 MATE, and 1
SMR transporter. Single-gene disruptions were created and
characterized in resistance assays. Four ABC-type MDR trans-
porters were identified as contributing significantly to intrinsic
drug resistance. Each constitutes a separate transport system,
with little overlap in the respective substrate spectra (30). The
analysis did not reveal a role for heterodimeric ABC transport-
ers in intrinsic resistance, even though EfrAB was described as
an MDR transporter of E. faecalis (69). EfrAB might, however,
contribute to acquired drug resistance.
Streptococcus pneumoniae
The genome of S. pneumoniae specifies 14 putative drug
efflux pumps. Except for the SP1435 gene, all putative MDR
genes were disrupted, and the resulting knockout strains were
analyzed for their drug resistance profiles. Only the deletion of
two linked genes, the SP2073 and SP2075 genes, each encoding
an ABC half-transporter, showed a significant decrease in re-
sistance towards acriflavine, ethidium bromide, berberine, and
norfloxacin. The individual knockout strains of SP2073 and
SP2075 showed identical patterns, suggesting that these two
proteins constitute a heterodimeric ABC-type MDR trans-
porter. Interestingly, SP2075 and SP2073 are close homologs
of the well-characterized LmrC and LmrD proteins from L.
lactis, bearing 56% and 57% identical residues, respectively, in
pairwise alignments (Table 2). Likewise, the deletion of the
lmrC and lmrD genes in L. lactis resulted in a drug-sensitive
phenotype, suggesting that homologs of LmrCD play an im-
portant role in the drug resistance of human pathogens. Im-
portantly, LmrCD homologs can also be identified in Strepto-
coccus pyogenes and Listeria monocytogenes, but their role in
drug resistance has not yet been addressed. A knockout mu-
tant of a previously identified MDR transporter, PmrA, be-
longing to the MFS, did not show altered sensitivity to tested
compounds (118). Again, this system may play a more domi-
nant role in acquired resistance.
Studies directed to detect efflux-based resistance have been
conducted with various important human pathogens. The in-
volvement of efflux systems in drug resistance has been dem-
onstrated for S. pneumoniae (26, 110), Staphylococcus aureus
(62), S. pyogenes (58), and various enterococci (84). Inhibitors
of mammalian MDR transporters, such as reserpine, biricodar
(VX-710), and timcodar (VX-853), increase the drug sensitiv-
ities of these strains. This global approach also demonstrated
efflux-based resistance mechanisms to a number of antibiotics
for three clinically significant gram-positive pathogens, Staph-
ylococcus aureus, E. faecalis, and S. pneumoniae (93). Again,
the molecular details of the resistance remain to be resolved.
Pst TRANSPORT SYSTEM AND MDR
The phosphate-specific transporter (Pst) has been well char-
acterized for E. coli and P. aeruginosa and specifies a high-
affinity, ATP-dependent transport system involved in phos-
phate uptake under starvation conditions, i.e., when the
phosphate concentration is below 1 mM (98, 134). The Pst
uptake system in Mycobacterium smegmatis has also been im-
plicated in drug efflux (11). Mutants highly resistant to fluoro-
quinolones (CIPr) overexpress the pstB gene. PstB is the NBD
of the ABC transporter involved in phosphate uptake (9). The
increased expression level of the pstB gene in a CIPr mutant
was due to up-regulation of the entire pst transport system
472 LUBELSKI ET AL. MICROBIOL. MOL. BIOL. REV.
 by on Septem









operon (17). Moreover, the CIPr mutant showed an increased
uptake of phosphate. Strikingly, inactivation of pstB in the
wild-type strain resulted in loss of the high-affinity phosphate
uptake activity and caused an increased sensitivity to fluoro-
quinolones (8, 11). Interestingly, a DNA microarray study of
gene expression in a daunomycin cross-resistant L. lactis mu-
tant strain revealed increased expression of the lactococcal pst
system (83). These studies suggest a role for phosphate trans-
port in drug resistance, but it is not clear if this relates to a
direct involvement of such transporters in drug extrusion or
reflects an indirect effect, for instance, by maximizing the gen-
eration of ATP due to an increased availability of inorganic
phosphate. Therefore, it will be interesting to investigate the
exact role of the Pst system in efflux-based MDR.
REGULATION OF MDR ABC TRANSPORTERS
Bacterial MDR transporters are usually subjected to tran-
scriptional regulation, which may involve several local tran-
scriptional regulators, repressors, or activators as well as global
transcriptional regulators. Local regulators are often found
adjacent to the structural genes of MDR transporters and
regulate the expression of the transporters depending on the
presence of substrates in the medium. Additionally, MDR
transporters are regulated by global modulators in response to
a global stress response (41, 42). The complex regulation of
MDR pumps may relate to the fact that these transporters can
potentially secrete valuable molecules from the cell. Like the
case with many other membrane proteins, the excessive over-
production of MDR transporters can be harmful for the cell,
but it remains to be determined if this involves specific activity-
related defects, such as interference with the integrity of the
membrane or the unwanted secretion of important metabolites
(41, 42).
The bacterial transcriptional regulators of MDR proteins
belong to four regulatory protein families, namely, AraC,
MarR, MerR, and TetR. All of these MDR regulators possess
the typical helix-turn-helix DNA-binding motif. Classification
of regulator families is mainly based on homology in the DNA-
binding domains (42). Several local regulators have been char-
acterized in great detail. These include BmrR from B. subtilis,
which is an activator of the MerR family that regulates the
expression of bmr (2). Binding of drugs such as TPP and
rhodamine 6G by BmrR results in an increased affinity of
BmrR for the bmr promoter and in subsequent transcriptional
activation of the expression of structural genes (89). Structural
studies in combination with biochemical analysis have shed
more light on the molecular basis of drug binding and the
molecular mechanism of BmrR (44). QacR is another well-
characterized regulator which represses its cognate gene, qacA.
Similar to BmrR, QacR interacts with toxic compounds, such
as ethidium and rhodamine 6G. However, in this case, drug
binding prevents binding of QacR to the target promoter,
thereby relieving the repression of qacA expression (40). The
structure of QacR has been solved and provides deeper insight
into the mechanism of drug recognition (127). Another MarR-
type repressor, EmrR, has been reported to regulate the
EmrAB efflux transporter of E. coli (80).
The expression of several MDR transporters has been
shown to be controlled by global regulators. The main MDR
transporter of E. coli, AcrAB, is regulated by the global acti-
vators MarA, Rob, and SoxS (4) and the local transcriptional
regulator AcrR. Similarly, in B. subtilis, two MDR transporters,
Bmr and Blt, are regulated by the local activators BmrR and
BltR and, at the global level, by the activator Mta (10). Also,
the involvement of two-component systems has been demon-
strated. Such systems consist of a histidine kinase that senses
drugs extracellularly and phosphorylates the response regula-
tor, which modulates the expression of MDR pumps. Some
examples are AlrSR (36), which regulates the expression of
NorA of S. aureus, and EvgAS (101), which modulates the
expression of the RND transporter YhiUV of E. coli.
Most of the described MDR pumps that are subject to reg-
ulation belong to the MFS and RND families, which are en-
ergized by the PMF, whereas members of the SMR family are
usually constitutively expressed and not subject to transcrip-
tional regulation (42). Since only limited numbers of ABC-type
MDR transporters have been studied, so far their regulation is
poorly understood. Recent observations demonstrated that
LmrCD of L. lactis is regulated by the local repressor YdaF
(83).
CONCLUSIONS
Since the initial discovery of MDR transporters in mamma-
lian cell lines by Dano in 1972 (24), the number of reported
MDR transporter-like proteins has expanded tremendously.
These systems belong to various structural and functional
groups, but historically, most emphasis in functional character-
ization has been on ion motive force-dependent systems. For a
long time, ABC-type transporters were underrepresented in
those studies. The genomic era allowed systematic studies of
MDR in prokaryotes, and now several ABC-type MDR trans-
porters have been identified as being involved in intrinsic and
acquired drug resistance in bacteria. Interestingly, the ABC-
type MDR transporters seem to fulfill a major role in drug
resistance of pathogenic gram-positive bacteria, such as E.
faecalis and S. pneumoniae (118). In these organisms, a ho-
molog of the heterodimeric ABC-type MDR transporter
LmrCD of L. lactis seems to be responsible for drug resistance.
Homologs of LmrCD are widely distributed among gram-pos-
itive bacteria, including many clinically significant pathogens
(Table 2). Interestingly, a homolog of LmrCD in S. pyogenes is
involved in stress responses and is needed for growth of S.
pyogenes at elevated temperatures (23). However, it will be
important to determine if this transporter also contributes to
virulence and resistance when patients are treated with drugs.
The systematic analysis of MDR transporters has also re-
sulted in the construction of a new generation of drug-hyper-
sensitive strains. Drug-hypersensitive E. coli strains lacking
several major MDR transporters have been postulated to rep-
resent potentially valuable tools for cell-based screens for an-
timicrobials (53). Similar strains of gram-positive bacteria
would be highly useful for MDR activity studies. In this re-
spect, the L. lactis lmrA lmrCD strain is highly sensitive to
several drugs, but since L. lactis contains other uncharacterized
putative MDR transporters, exploitation of such a strain for
drug screening awaits further gene knockout analysis. Like-
wise, similar strains of pathogenic prokaryotes can be foreseen
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and will provide greater insight into the natural role of these
systems.
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